Patients with age-related macular degeneration are known to experience high rates of depression and anxiety, but clinicians often miss the problems, prompting a call for a consensus statement.
Despite the overall survival benefit associated with fruquintinib, weighing the risks and benefits of the drug remains important; and one oncologist questioned the trial s placebo arm.
Merck and Eisai said on Friday they were discontinuing a late-stage study of Keytruda plus Lenvima for the treatment of adults with unresectable or metastatic melanoma.